1. Home
  2. ALXO vs AIRE Comparison

ALXO vs AIRE Comparison

Compare ALXO & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.47

Market Cap

79.7M

Sector

Health Care

ML Signal

HOLD

Logo reAlpha Tech Corp.

AIRE

reAlpha Tech Corp.

HOLD

Current Price

$0.50

Market Cap

40.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALXO
AIRE
Founded
2015
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.7M
40.7M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ALXO
AIRE
Price
$1.47
$0.50
Analyst Decision
Strong Buy
Buy
Analyst Count
6
2
Target Price
$3.30
$2.00
AVG Volume (30 Days)
270.6K
3.9M
Earning Date
11-07-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,149,567.00
Revenue This Year
N/A
$411.48
Revenue Next Year
N/A
$141.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
994.18
52 Week Low
$0.40
$0.14
52 Week High
$2.27
$4.49

Technical Indicators

Market Signals
Indicator
ALXO
AIRE
Relative Strength Index (RSI) 51.75 45.87
Support Level $1.29 $0.51
Resistance Level $1.57 $0.56
Average True Range (ATR) 0.11 0.05
MACD 0.02 0.01
Stochastic Oscillator 67.50 37.10

Price Performance

Historical Comparison
ALXO
AIRE

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.

Share on Social Networks: